WO2002070010A1 - Inhibiteurs de rejet du greffon - Google Patents

Inhibiteurs de rejet du greffon Download PDF

Info

Publication number: WO2002070010A1
Authority: WO; WIPO (PCT)
Prior art keywords: graft rejection; ailim; organs; rejection inhibitors; inhibitors
Prior art date: 2001-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/JP2002/000930

Other languages

English (en)

French (fr)

Inventor

Seiichi Suzuki

Mitsuaki Isobe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Japan Tobacco Inc

Original Assignee

Japan Tobacco Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-01

Filing date

2002-02-05

Publication date

2002-09-12

2000-12-08 Priority to HK03105544.7A priority Critical patent/HK1053266B/xx

2002-02-05 Priority to EP02710508A priority patent/EP1374901B9/en

2002-02-05 Priority to HU0303332A priority patent/HU228045B1/hu

2002-02-05 Priority to KR1020037011255A priority patent/KR100609444B1/ko

2002-02-05 Priority to MXPA03006736A priority patent/MXPA03006736A/es

2002-02-05 Priority to CN028058054A priority patent/CN1518458B/zh

2002-02-05 Priority to BR0207787-6A priority patent/BR0207787A/pt

2002-02-05 Priority to NZ527076A priority patent/NZ527076A/xx

2002-02-05 Priority to CA002439858A priority patent/CA2439858C/en

2002-02-05 Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc

2002-02-05 Priority to RU2003129166/15A priority patent/RU2263512C2/ru

2002-02-05 Priority to DE60217839T priority patent/DE60217839T2/de

2002-02-05 Priority to HK04104524.3A priority patent/HK1061531B/en

2002-02-05 Priority to SK1214-2003A priority patent/SK288048B6/sk

2002-02-05 Priority to IL15684502A priority patent/IL156845A0/xx

2002-02-05 Priority to AU2002228435A priority patent/AU2002228435B2/en

2002-09-12 Publication of WO2002070010A1 publication Critical patent/WO2002070010A1/ja

2003-07-09 Priority to IL156845A priority patent/IL156845A/en

2003-08-29 Priority to NO20033839A priority patent/NO331690B1/no

2003-09-01 Anticipated expiration legal-status Critical

2004-03-04 Priority to US10/793,171 priority patent/US7438905B2/en

2008-09-12 Priority to US12/209,643 priority patent/US20090047292A1/en

2011-02-08 Priority to NO20110218A priority patent/NO20110218L/no

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Graft Or Block Polymers (AREA)
External Artificial Organs (AREA)
Transplanting Machines (AREA)
Soil Working Implements (AREA)
Cylinder Crankcases Of Internal Combustion Engines (AREA)

PCT/JP2002/000930 1999-12-10 2002-02-05 Inhibiteurs de rejet du greffon Ceased WO2002070010A1 (fr)

Priority Applications (20)

Application Number	Priority Date	Filing Date	Title
HK03105544.7A HK1053266B (en)	1999-12-10	2000-12-08	Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE60217839T DE60217839T2 (de)	2001-03-01	2002-02-05	Mittel zur suppression von transplantat-abstossung
KR1020037011255A KR100609444B1 (ko)	2001-03-01	2002-02-05	이식편 거절반응 억제제
MXPA03006736A MXPA03006736A (es)	2001-03-01	2002-02-05	Supresores del rechazamiento de injerto.
CN028058054A CN1518458B (zh)	2001-03-01	2002-02-05	移植物排斥反应抑制剂
BR0207787-6A BR0207787A (pt)	2001-03-01	2002-02-05	Supressores de rejeição de enxertos
NZ527076A NZ527076A (en)	2001-03-01	2002-02-05	Graft rejection inhibitors used in combination with immunosuppressants
SK1214-2003A SK288048B6 (sk)	2001-03-01	2002-02-05	Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection
HU0303332A HU228045B1 (en)	2001-03-01	2002-02-05	Graft rejection suppressing agents
RU2003129166/15A RU2263512C2 (ru)	2001-03-01	2002-02-05	Средства, подавляющие отторжение трансплантата
HK04104524.3A HK1061531B (en)	2001-03-01	2002-02-05	Graft rejection suppressors
EP02710508A EP1374901B9 (en)	2001-03-01	2002-02-05	Graft rejection suppressors
CA002439858A CA2439858C (en)	2001-03-01	2002-02-05	Graft rejection suppressors
IL15684502A IL156845A0 (en)	2001-03-01	2002-02-05	Graft rejection suppressors
AU2002228435A AU2002228435B2 (en)	2001-03-01	2002-02-05	Graft rejection inhibitors
IL156845A IL156845A (en)	2001-03-01	2003-07-09	Use of substances that affect the activity of AILIM for the preparation of a drug to prevent implant rejection
NO20033839A NO331690B1 (no)	2001-03-01	2003-08-29	Forbindelse, og farmasoytisk kombinasjon av forbindelse, som har en aktivitet til a modulere signaloverforing formidlet av AILIM for forsterkning av virkningen av immunsupprimerende midler pa undertrykkelse, behandling eller forebyggelse av transplantatavstotning ved transplantasjon av et organ, del av et organ eller et vev.
US10/793,171 US7438905B2 (en)	2001-03-01	2004-03-04	Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US12/209,643 US20090047292A1 (en)	2001-03-01	2008-09-12	Graft rejection suppressors
NO20110218A NO20110218L (no)	2001-03-01	2011-02-08	Transplantatrejeksjonssuppressorer

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
JP2001056209		2001-03-01
JP2001-56216		2001-03-01
JP2001-56209		2001-03-01
JP2001056216		2001-03-01
JP2002-8028		2002-01-16
JP2002008028		2002-01-16

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
US10451972 A-371-Of-International		2002-02-05
US10/793,171 Continuation-In-Part US7438905B2 (en)	2001-03-01	2004-03-04	Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM

Publications (1)

Publication Number	Publication Date
WO2002070010A1 true WO2002070010A1 (fr)	2002-09-12

Family

ID=27346134

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/000930 Ceased WO2002070010A1 (fr)	1999-12-10	2002-02-05	Inhibiteurs de rejet du greffon

Country Status (24)

Country	Link
US (2)	US7438905B2 (ja)
EP (2)	EP1374901B9 (ja)
JP (1)	JP4212278B2 (ja)
KR (1)	KR100609444B1 (ja)
CN (1)	CN1518458B (ja)
AT (2)	ATE352318T1 (ja)
AU (1)	AU2002228435B2 (ja)
BR (1)	BR0207787A (ja)
CA (1)	CA2439858C (ja)
CY (1)	CY1110143T1 (ja)
CZ (1)	CZ20032406A3 (ja)
DE (2)	DE60217839T2 (ja)
DK (1)	DK1769807T3 (ja)
ES (1)	ES2344219T3 (ja)
HU (2)	HU228045B1 (ja)
IL (2)	IL156845A0 (ja)
MX (1)	MXPA03006736A (ja)
NO (2)	NO331690B1 (ja)
NZ (1)	NZ527076A (ja)
PT (1)	PT1769807E (ja)
RU (1)	RU2263512C2 (ja)
SI (1)	SI1769807T1 (ja)
SK (1)	SK288048B6 (ja)
WO (1)	WO2002070010A1 (ja)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6803039B2 (en)	2000-05-18	2004-10-12	Japan Tobacco Inc.	Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7030225B1 (en)	1997-02-27	2006-04-18	Japan Tobacco, Inc.	Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en)	1997-02-27	2006-05-16	Japan Tobacco, Inc.	Nucleic acids encoding JTT-1 protein
US7438905B2 (en)	2001-03-01	2008-10-21	Japan Tobacco, Inc.	Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en)	2001-03-27	2008-12-16	Japan Tobacco, Inc.	Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US7465445B2 (en)	1999-08-30	2008-12-16	Japan Tobacco Inc.	Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
WO2017220989A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
WO2018029474A2 (en)	2016-08-09	2018-02-15	Kymab Limited	Anti-icos antibodies
WO2019122884A1 (en)	2017-12-19	2019-06-27	Kymab Limited	Antibodies to icos
WO2021229032A1 (en)	2020-05-14	2021-11-18	Kymab Limited	Tumour biomarkers for immunotherapy
WO2022243378A1 (en)	2021-05-18	2022-11-24	Kymab Limited	Uses of anti-icos antibodies
WO2022254227A1 (en)	2021-06-04	2022-12-08	Kymab Limited	Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
WO2023222854A1 (en)	2022-05-18	2023-11-23	Kymab Limited	Uses of anti-icos antibodies
RU2833126C2 (ru) *	2022-11-15	2025-01-14	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России)	Способ профилактики несостоятельности трансплантата аллогенного костного мозга или гемопоэтических стволовых клеток при наличии у реципиента донор-специфичных анти-HLA антител

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19821060A1 (de) *	1997-09-23	1999-04-15	Bundesrepublik Deutschland Let	Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
HRP20050176A2 (en) *	1999-12-16	2005-08-31	Teva Pharmaceutical Industries Ltd.	Novel processes for making - and a new crystalline form of-leflunomide
RU2291675C2 (ru) *	2004-07-09	2007-01-20	Институт теоретической и экспериментальной биофизики РАН	Способ обработки трансплантатов для сердечно-сосудистой хирургии
GB0504544D0 (en) *	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
JP2006321765A (ja) *	2005-05-20	2006-11-30	Mikiko Ueda	肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬
AU2008247382B2 (en) *	2007-05-07	2014-06-05	Medimmune, Llc	Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9931386B2 (en) *	2008-06-16	2018-04-03	Atsuo Ochi	Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
WO2011007747A1 (ja)	2009-07-16	2011-01-20	大塚化学株式会社	糖鎖付加ａｉｌｉｍ細胞外ドメイン及びその製造方法
US9420770B2 (en)	2009-12-01	2016-08-23	Indiana University Research & Technology Corporation	Methods of modulating thrombocytopenia and modified transgenic pigs
EP2558024B1 (en) *	2010-04-12	2017-03-08	The University Of Miami	Macroporous bioengineered scaffolds for cell transplantation
KR101905113B1 (ko) *	2011-03-31	2018-10-10	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	Icos에 대한 항체 및 이의 용도
US20150139994A1 (en) *	2013-11-12	2015-05-21	The Regents Of The University Of California	Compositions and methods for preventing allogeneic immune rejection
CN105744949A (zh) *	2013-11-22	2016-07-06	夏尔维洛药品公司	用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
CA2942384C (en)	2014-03-12	2024-01-23	Icahn School Of Medicine At Mount Sinai	Method for identifying kidney allograft recipients at risk for chronic injury
ES2850281T3 (es)	2014-06-26	2021-08-26	Icahn School Med Mount Sinai	Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
CA2953368C (en) *	2014-06-26	2022-11-08	Icahn School Of Medicine At Mount Sinai	Methods for diagnosing risk of renal allograft fibrosis and rejection
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
HK1250032A1 (zh)	2015-12-03	2018-11-23	Glaxosmithkline Intellectual Property Development Limited	作为sting调节剂的环状嘌呤二核苷酸
WO2017098421A1 (en)	2015-12-08	2017-06-15	Glaxosmithkline Intellectual Property Development Limited	Benzothiadiazine compounds
WO2017153952A1 (en)	2016-03-10	2017-09-14	Glaxosmithkline Intellectual Property Development Limited	5-sulfamoyl-2-hydroxybenzamide derivatives
CN109563081A (zh)	2016-04-07	2019-04-02	葛兰素史克知识产权开发有限公司	可用作蛋白调节剂的杂环酰胺类
MX387354B (es)	2016-04-07	2025-03-18	Glaxosmithkline Ip Dev Ltd	Amidas heterocíclicas útiles como moduladores de proteínas.
PE20190106A1 (es)	2016-05-05	2019-01-15	Glaxosmithkline Ip No 2 Ltd	Inhibidores del potenciador del homologo zeste 2
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
WO2018015879A1 (en)	2016-07-20	2018-01-25	Glaxosmithkline Intellectual Property Development Limited	Isoquinoline derivatives as perk inhibitors
CN116640214A (zh)	2016-08-09	2023-08-25	科马布有限公司	分离抗体及其应用
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200062735A1 (en)	2017-02-27	2020-02-27	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
CN110869049A (zh)	2017-06-09	2020-03-06	葛兰素史克知识产权开发有限公司	组合疗法
CA3066038A1 (en)	2017-06-09	2018-12-13	Glaxosmithkline Intellectual Property Development Limited	Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225035A1 (en)	2017-06-09	2018-12-13	Glaxosmithkline Intellectual Property Development Limited	Combination therapy with icos agonist and ox40 agonist to treat cancer
GB201709808D0 (en)	2017-06-20	2017-08-02	Kymab Ltd	Antibodies
WO2019021208A1 (en)	2017-07-27	2019-01-31	Glaxosmithkline Intellectual Property Development Limited	USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en)	2017-09-12	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	CHEMICAL COMPOUNDS
JP2020533380A (ja)	2017-09-14	2020-11-19	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	癌の組合せ治療
EP3692033A1 (en)	2017-10-05	2020-08-12	GlaxoSmithKline Intellectual Property Development Limited	Modulators of stimulator of interferon genes (sting) useful in treating hiv
US11377440B2 (en)	2017-10-05	2022-07-05	Glaxosmithkline Intellectual Property Development Limited	Modulators of stimulator of interferon genes (STING)
WO2019122882A1 (en)	2017-12-19	2019-06-27	Kymab Limited	Bispecific antibody for icos and pd-l1
RU2688172C1 (ru) *	2018-04-05	2019-05-20	Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского)	Способ профилактики отторжения трансплантата трупной почки
ES3037279T3 (en)	2018-04-16	2025-09-30	Icahn School Med Mount Sinai	Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
GB201807924D0 (en)	2018-05-16	2018-06-27	Ctxt Pty Ltd	Compounds
EP3801615A1 (en)	2018-05-31	2021-04-14	GlaxoSmithKline Intellectual Property Development Ltd	Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
US20210267973A1 (en)	2018-05-31	2021-09-02	Glaxosmithkline Intellectual Property Development Limited	Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
WO2020031087A1 (en)	2018-08-06	2020-02-13	Glaxosmithkline Intellectual Property Development Limited	Combination therapy
WO2020086479A1 (en)	2018-10-22	2020-04-30	Glaxosmithkline Intellectual Property Development Limited	Dosing
US20200368369A1 (en) *	2019-05-22	2020-11-26	Wyvern Pharmaceuticals Inc.	Composition for endogenous production of checkpoint protein precursors
GB201910305D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
GB201910304D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
WO2021018941A1 (en)	2019-07-31	2021-02-04	Glaxosmithkline Intellectual Property Development Limited	Methods of treating cancer
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
PH12022550671A1 (en)	2019-09-27	2023-05-29	Glaxosmithkline Ip Dev Ltd	Antigen binding proteins
CA3164751A1 (en)	2019-12-18	2021-06-24	Benjamin Joseph MORROW	Compounds
CN113294813B (zh) *	2020-02-24	2022-09-02	宁波方太厨具有限公司	一种电磁灶
CN115397861A (zh)	2020-04-14	2022-11-25	葛兰素史密斯克莱知识产权发展有限公司	用于癌症的组合治疗
CA3171557A1 (en)	2020-04-14	2021-10-21	Marc S. BALLAS	Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
WO2021209358A1 (en)	2020-04-14	2021-10-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
JP2024509529A (ja)	2021-03-02	2024-03-04	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	Ｄｎｍｔ１阻害剤としての置換ピリジン
WO2022208353A1 (en)	2021-03-31	2022-10-06	Glaxosmithkline Intellectual Property Development Limited	Antigen binding proteins and combinations thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995033770A1 (en) *	1994-06-03	1995-12-14	Repligen Corporation	Ligands for induction of antigen specific apoptosis in t cells
WO1998019706A1 (en) *	1996-11-08	1998-05-14	Idec Pharmaceuticals Corporation	Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038206A1 (en) *	1997-02-26	1998-09-03	Raisio Benecol Ltd.	Process for the preparation of stanol esters
JPH11228442A (ja) *	1998-02-09	1999-08-24	Cypros Pharmaceut Corp	臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) *	1998-09-14	2000-06-06	Kyo Jo	免疫抑制剤
WO2000046240A2 (en) *	1999-02-03	2000-08-10	Amgen Inc.	Polypeptides involved in immune response
WO2001015732A1 (en) *	1999-08-30	2001-03-08	Japan Tobacco Inc.	Remedies for immunological diseases
WO2001087981A2 (en) *	2000-05-18	2001-11-22	Japan Tobacco, Inc.	Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506126A (en) *	1988-02-25	1996-04-09	The General Hospital Corporation	Rapid immunoselection cloning method
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5580756A (en) *	1990-03-26	1996-12-03	Bristol-Myers Squibb Co.	B7Ig fusion protein
CN1188528C (zh) *	1991-06-11	2005-02-09	血液研究中心	细胞间粘附分子－3及其配体
US5770197A (en) *	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja)	1991-09-12	2001-04-25	住友製薬株式会社	高感度特異的抗体測定法
US5484892A (en) *	1993-05-21	1996-01-16	Dana-Farber Cancer Institute, Inc.	Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5747461A (en) *	1994-07-26	1998-05-05	Markov; Angel K.	Synergistic administration of cyclosporine and fructose diphosphate
US5914112A (en) *	1996-01-23	1999-06-22	Genentech, Inc.	Anti-CD18 antibodies in stroke
CA2242414C (en)	1996-01-23	2012-01-03	Genentech, Inc.	Anti-cd18 antibodies for use against stroke
IL129024A0 (en)	1996-09-18	2000-02-17	Zetesis Spa	Use of proteins as agent against autoimmune diseases
WO1998037415A1 (en)	1997-02-20	1998-08-27	The Regents Of The University Of California	ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
US7112655B1 (en) *	1997-02-27	2006-09-26	Japan Tobacco, Inc.	JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja)	1997-02-27	2004-04-19	日本たばこ産業株式会社	細胞間接着及びシグナル伝達を媒介する細胞表面分子
DK1325932T5 (da)	1997-04-07	2005-10-03	Genentech Inc	Anti-VEGF antistoffer
CA2305350C (en) *	1997-09-23	2015-04-07	Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts	Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) *	1997-09-23	1999-04-15	Bundesrepublik Deutschland Let	Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
AU767241B2 (en) *	1998-09-14	2003-11-06	Qiang Xu	Immunosuppressive agents
WO2000019988A1 (en)	1998-10-07	2000-04-13	Millennium Pharmaceuticals, Inc.	NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
BR0010711A (pt)	1999-05-06	2002-02-13	Genetics Inst	Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
AU6615500A (en)	1999-07-28	2001-02-19	Genetics Institute Inc.	Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en)	1999-08-11	2001-02-22	Isis Innovations Limited	Human icos ligand and application thereof
JP4210454B2 (ja)	2001-03-27	2009-01-21	日本たばこ産業株式会社	炎症性腸疾患治療剤
JP2003508088A (ja)	1999-09-03	2003-03-04	ヒューマンジノームサイエンシーズ，インコーポレイテッド	５２個のヒト分泌タンパク質
JP4737905B2 (ja)	1999-09-21	2011-08-03	ジェネティクスインスティテュート，エルエルシー	Ｇｌ５０分子およびその使用
EP1224201A4 (en)	1999-10-29	2005-03-02	Human Genome Sciences Inc	32 HUMAN SECRETED PROTEINS
WO2001064704A1 (en)	2000-03-02	2001-09-07	Mayo Foundation For Medical Education And Research	hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
AU1796902A (en)	2000-11-28	2002-06-11	Amgen Inc	Novel polypeptides involved in immune response
JP4212278B2 (ja)	2001-03-01	2009-01-21	日本たばこ産業株式会社	移植片拒絶反応抑制剤

2002
- 2002-01-22 JP JP2002013189A patent/JP4212278B2/ja not_active Expired - Fee Related
- 2002-02-05 AT AT02710508T patent/ATE352318T1/de not_active IP Right Cessation
- 2002-02-05 MX MXPA03006736A patent/MXPA03006736A/es active IP Right Grant
- 2002-02-05 EP EP02710508A patent/EP1374901B9/en not_active Expired - Lifetime
- 2002-02-05 CA CA002439858A patent/CA2439858C/en not_active Expired - Fee Related
- 2002-02-05 AU AU2002228435A patent/AU2002228435B2/en not_active Ceased
- 2002-02-05 HU HU0303332A patent/HU228045B1/hu not_active IP Right Cessation
- 2002-02-05 KR KR1020037011255A patent/KR100609444B1/ko not_active Expired - Fee Related
- 2002-02-05 DE DE60217839T patent/DE60217839T2/de not_active Expired - Lifetime
- 2002-02-05 WO PCT/JP2002/000930 patent/WO2002070010A1/ja not_active Ceased
- 2002-02-05 CZ CZ20032406A patent/CZ20032406A3/cs unknown
- 2002-02-05 IL IL15684502A patent/IL156845A0/xx active IP Right Grant
- 2002-02-05 RU RU2003129166/15A patent/RU2263512C2/ru not_active IP Right Cessation
- 2002-02-05 SI SI200230901T patent/SI1769807T1/sl unknown
- 2002-02-05 DK DK06024523.0T patent/DK1769807T3/da active
- 2002-02-05 BR BR0207787-6A patent/BR0207787A/pt not_active IP Right Cessation
- 2002-02-05 SK SK1214-2003A patent/SK288048B6/sk not_active IP Right Cessation
- 2002-02-05 AT AT06024523T patent/ATE463256T1/de active
- 2002-02-05 ES ES06024523T patent/ES2344219T3/es not_active Expired - Lifetime
- 2002-02-05 HU HU1100018A patent/HU228108B1/hu not_active IP Right Cessation
- 2002-02-05 NZ NZ527076A patent/NZ527076A/xx not_active IP Right Cessation
- 2002-02-05 EP EP06024523A patent/EP1769807B1/en not_active Expired - Lifetime
- 2002-02-05 PT PT06024523T patent/PT1769807E/pt unknown
- 2002-02-05 DE DE60235928T patent/DE60235928D1/de not_active Expired - Lifetime
- 2002-02-05 CN CN028058054A patent/CN1518458B/zh not_active Expired - Fee Related
2003
- 2003-07-09 IL IL156845A patent/IL156845A/en not_active IP Right Cessation
- 2003-08-29 NO NO20033839A patent/NO331690B1/no not_active IP Right Cessation
2004
- 2004-03-04 US US10/793,171 patent/US7438905B2/en not_active Expired - Fee Related
2008
- 2008-09-12 US US12/209,643 patent/US20090047292A1/en not_active Abandoned
2010
- 2010-06-04 CY CY20101100496T patent/CY1110143T1/el unknown
2011
- 2011-02-08 NO NO20110218A patent/NO20110218L/no not_active Application Discontinuation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995033770A1 (en) *	1994-06-03	1995-12-14	Repligen Corporation	Ligands for induction of antigen specific apoptosis in t cells
WO1998019706A1 (en) *	1996-11-08	1998-05-14	Idec Pharmaceuticals Corporation	Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038206A1 (en) *	1997-02-26	1998-09-03	Raisio Benecol Ltd.	Process for the preparation of stanol esters
JPH11228442A (ja) *	1998-02-09	1999-08-24	Cypros Pharmaceut Corp	臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) *	1998-09-14	2000-06-06	Kyo Jo	免疫抑制剤
WO2000046240A2 (en) *	1999-02-03	2000-08-10	Amgen Inc.	Polypeptides involved in immune response
WO2001015732A1 (en) *	1999-08-30	2001-03-08	Japan Tobacco Inc.	Remedies for immunological diseases
WO2001087981A2 (en) *	2000-05-18	2001-11-22	Japan Tobacco, Inc.	Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUTLOFF ANDREAS: "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28", NATURE, vol. 397, January 1999 (1999-01-01), pages 263 - 266, XP002156736 *
KENICHIRO KIYONO: "Fukushigeki no sogai no yoru kanyo yudo", IGAKU NO AYUMI, vol. 196, no. 13, 31 March 2001 (2001-03-31), pages 949 - 952, XP002955855 *
OGAWA SHU-HEI ET AL.: "Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-horst disease", J. IMMUNOL., vol. 167, no. 10, November 2001 (2001-11-01), pages 5741 - 5748, XP002950182 *
TAFURI ANNA ET AL.: "ICOS is essential for effective T-help er-cell responses", NATURE, vol. 409, January 2001 (2001-01-01), pages 105 - 109, XP002950181 *
YOSHINAGA STEVEN K. ET AL.: "T-cell co-stimulation through B7RP-1 and ICOS", NATURE, vol. 402, December 1999 (1999-12-01), pages 827 - 832, XP002157212 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7932358B2 (en)	1997-02-27	2011-04-26	Japan Tobacco Inc.	Antibodies to JTT-1 protein and cells secreting such antibodies
US7030225B1 (en)	1997-02-27	2006-04-18	Japan Tobacco, Inc.	Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en)	1997-02-27	2006-05-16	Japan Tobacco, Inc.	Nucleic acids encoding JTT-1 protein
US7112655B1 (en)	1997-02-27	2006-09-26	Japan Tobacco, Inc.	JTT-1 protein and methods of inhibiting lymphocyte activation
US8389690B2 (en)	1997-02-27	2013-03-05	Japan Tobacco Inc.	Antibodies to JTT-1 protein and cells secreting such antibodies
US7196175B2 (en)	1997-02-27	2007-03-27	Japan Tobacco Inc.	Antibodies to JTT-1 protein and cells secreting such antibodies
US7217792B2 (en)	1997-02-27	2007-05-15	Japan Tobacco Inc.	JTT-1 protein and methods of inhibiting lymphocyte activation
US7226909B2 (en)	1997-02-27	2007-06-05	Japan Tobacco Inc.	Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7247612B2 (en)	1997-02-27	2007-07-24	Japan Tobacco Inc.	Methods of treating an inflammatory disease with a JJT-1 polypeptide
US7259147B2 (en)	1997-02-27	2007-08-21	Japan Tobacco Inc.	Methods of treating multiple sclerosis with a JTT-1 polypeptide
US7279560B2 (en)	1997-02-27	2007-10-09	Japan Tobacco Inc.	Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
US7294473B2 (en)	1997-02-27	2007-11-13	Japan Tobacco Inc.	Methods of identifying substances that interact with JTT-1 protein
US7465445B2 (en)	1999-08-30	2008-12-16	Japan Tobacco Inc.	Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
US7998478B2 (en)	1999-08-30	2011-08-16	Japan Tobacco, Inc.	Pharmaceutical composition for treating immune diseases
US6803039B2 (en)	2000-05-18	2004-10-12	Japan Tobacco Inc.	Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7988965B2 (en)	2000-05-18	2011-08-02	Japan Tobacco, Inc.	Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim
US7166283B2 (en)	2000-05-18	2007-01-23	Japan Tobacco Inc.	Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
US7438905B2 (en)	2001-03-01	2008-10-21	Japan Tobacco, Inc.	Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en)	2001-03-27	2008-12-16	Japan Tobacco, Inc.	Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US8052972B2 (en)	2001-03-27	2011-11-08	Japan Tobacco, Inc.	Remedies for inflammatory bowel diseases
WO2017220988A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Multispecific antibodies for immuno-oncology
WO2017220989A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
WO2017220990A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 antibodies
WO2018029474A2 (en)	2016-08-09	2018-02-15	Kymab Limited	Anti-icos antibodies
WO2019122884A1 (en)	2017-12-19	2019-06-27	Kymab Limited	Antibodies to icos
WO2021229032A1 (en)	2020-05-14	2021-11-18	Kymab Limited	Tumour biomarkers for immunotherapy
WO2022243378A1 (en)	2021-05-18	2022-11-24	Kymab Limited	Uses of anti-icos antibodies
WO2022254227A1 (en)	2021-06-04	2022-12-08	Kymab Limited	Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
WO2023222854A1 (en)	2022-05-18	2023-11-23	Kymab Limited	Uses of anti-icos antibodies
RU2833126C2 (ru) *	2022-11-15	2025-01-14	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России)	Способ профилактики несостоятельности трансплантата аллогенного костного мозга или гемопоэтических стволовых клеток при наличии у реципиента донор-специфичных анти-HLA антител

Also Published As

Publication number	Publication date
DK1769807T3 (da)	2010-07-19
HUP0303332A2 (hu)	2003-12-29
EP1374901A4 (en)	2004-09-15
RU2003129166A (ru)	2005-03-10
EP1374901B9 (en)	2007-11-07
DE60217839D1 (de)	2007-03-15
CN1518458B (zh)	2010-05-26
NO20033839L (no)	2003-11-03
CN1518458A (zh)	2004-08-04
HK1102293A1 (en)	2007-11-16
CA2439858A1 (en)	2002-09-12
PT1769807E (pt)	2010-06-02
DE60217839T2 (de)	2007-11-15
EP1769807A1 (en)	2007-04-04
EP1769807B1 (en)	2010-04-07
ES2344219T3 (es)	2010-08-20
IL156845A (en)	2011-10-31
ATE463256T1 (de)	2010-04-15
BR0207787A (pt)	2004-03-23
MXPA03006736A (es)	2004-05-31
AU2002228435B2 (en)	2005-03-10
EP1374901B1 (en)	2007-01-24
KR100609444B1 (ko)	2006-08-03
US20040253229A1 (en)	2004-12-16
SK12142003A3 (sk)	2004-05-04
JP4212278B2 (ja)	2009-01-21
US20090047292A1 (en)	2009-02-19
DE60235928D1 (de)	2010-05-20
HK1061531A1 (en)	2004-09-24
HU228108B1 (en)	2012-11-28
RU2263512C2 (ru)	2005-11-10
ATE352318T1 (de)	2007-02-15
SK288048B6 (sk)	2013-03-01
CA2439858C (en)	2009-07-14
CY1110143T1 (el)	2015-01-14
EP1374901A1 (en)	2004-01-02
NO331690B1 (no)	2012-02-27
SI1769807T1 (sl)	2010-08-31
NZ527076A (en)	2006-03-31
CZ20032406A3 (cs)	2004-10-13
US7438905B2 (en)	2008-10-21
HU228045B1 (en)	2012-09-28
NO20110218L (no)	2003-11-03
IL156845A0 (en)	2004-02-08
NO20033839D0 (no)	2003-08-29
KR20030078946A (ko)	2003-10-08
JP2003277293A (ja)	2003-10-02

Publication	Publication Date	Title
WO2002070010A1 (fr)	2002-09-12	Inhibiteurs de rejet du greffon
WO2004050026A3 (en)	2004-08-19	Compositions and methods for treating prostate cancer
WO2004024093A3 (en)	2004-07-29	Device and method for treating restenosis
WO2004043293A3 (en)	2005-02-17	Cardiac valve procedure methods and devices
WO2004043374A3 (en)	2004-08-12	Methods and compositions for treating cancer using proteasome inhibitors
WO2007149999A3 (en)	2008-10-16	Compositions and methods for joining non-conjoined lumens
WO2001005392A3 (en)	2001-07-19	Method for treating chronic pain using mek inhibitors
WO2004039248A3 (en)	2004-10-14	Repairing or replacing tissues or organs
MY137250A (en)	2009-01-30	Method of treatment of transplant rejection
WO2006042100A3 (en)	2007-06-07	Method for the treatment of polycystic kidney disease
ATE250932T1 (de)	2003-10-15	Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
EP1751272B8 (en)	2009-04-15	Production of tacrolimus (fk-506) using new streptomyces species
EP2258702A3 (en)	2011-11-30	Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
DK1178726T3 (da)	2003-06-10	Vandig opløsning til konservering af væv og organer
WO2005110479A3 (en)	2006-02-09	Treatments for pancreatic cancer
WO2022130017A3 (en)	2022-07-28	Processing of tumor infiltrating lymphocytes
WO2004052305A3 (en)	2005-06-16	Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2006077592A3 (en)	2006-11-02	Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
ATE335475T1 (de)	2006-09-15	Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
WO2005081972A3 (en)	2006-01-05	Maleiimide anti-tumor phosphatase inhibitors
WO2005058243A3 (en)	2006-12-28	Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a
DE60117762D1 (de)	2006-05-04	Vitamin d-verbindungen zur behandlung von chronischer tranplantatnephropathie bei nieren transplantieren patienten
NO20016316L (no)	2002-01-30	Fremgangsmåte til å behandle eller forhindre kransarterietransplantasjonsvasospasme
WO2003039231A3 (en)	2003-10-16	Compounds and methods for treating transplant rejection
WO2004075977A3 (en)	2005-03-10	Methods using diffuse field ultrasound-induced hyperthermia

Legal Events

Date	Code	Title	Description
2002-09-12	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
2002-09-12	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2002-11-06	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-03-06	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-07-09	WWE	Wipo information: entry into national phase	Ref document number: 156845 Country of ref document: IL
2003-07-11	WWE	Wipo information: entry into national phase	Ref document number: 2002228435 Country of ref document: AU
2003-07-18	WWE	Wipo information: entry into national phase	Ref document number: 527076 Country of ref document: NZ
2003-07-28	WWE	Wipo information: entry into national phase	Ref document number: PA/a/2003/006736 Country of ref document: MX
2003-08-21	WWE	Wipo information: entry into national phase	Ref document number: 2003/06516 Country of ref document: ZA Ref document number: 200306516 Country of ref document: ZA
2003-08-27	WWE	Wipo information: entry into national phase	Ref document number: 1020037011255 Country of ref document: KR
2003-09-01	WWE	Wipo information: entry into national phase	Ref document number: 028058054 Country of ref document: CN
2003-09-02	WWE	Wipo information: entry into national phase	Ref document number: 2439858 Country of ref document: CA
2003-09-05	WWE	Wipo information: entry into national phase	Ref document number: PV2003-2406 Country of ref document: CZ
2003-09-29	WWE	Wipo information: entry into national phase	Ref document number: 12142003 Country of ref document: SK Ref document number: 1538/CHENP/2003 Country of ref document: IN Ref document number: 1200300859 Country of ref document: VN
2003-10-01	WWE	Wipo information: entry into national phase	Ref document number: 2002710508 Country of ref document: EP
2003-10-08	WWP	Wipo information: published in national office	Ref document number: 1020037011255 Country of ref document: KR
2004-01-02	WWP	Wipo information: published in national office	Ref document number: 2002710508 Country of ref document: EP
2004-01-15	REG	Reference to national code	Ref country code: DE Ref legal event code: 8642
2004-10-13	WWP	Wipo information: published in national office	Ref document number: PV2003-2406 Country of ref document: CZ
2005-06-23	WWG	Wipo information: grant in national office	Ref document number: 2002228435 Country of ref document: AU
2006-03-31	WWP	Wipo information: published in national office	Ref document number: 527076 Country of ref document: NZ
2007-01-24	WWG	Wipo information: grant in national office	Ref document number: 2002710508 Country of ref document: EP